C1q Complement – A Potential Biomarker to Determine Plaque Vulnerability in Coronary Heart Disease

by Shilpi Aggarwal, PhD, Freelance Writer

In a new research article published on April 25, 2024, in Scientific Reports, researchers have proposed the potential use of serum measurements of C1q complement as a relevant biomarker to determine plaque stability in coronary artery disease (CAD) patients and for the assessment of the disease. The open-access article is titled “The Relationship Between Complement C1q and Coronary Plaque Vulnerability Based on Optical Coherence Tomography Analysis.” This conclusion arises from a retrospective observational study done by the researchers using data on plaque morphology and C1 complement serum levels for 221 CAD patients who were admitted to The Second Affiliated Hospital of Xi’an Jiaotong University in China between April 2021 and July 2022 and underwent simultaneous coronary angiography and optical coherence tomography (OCT) evaluation. The researchers initiated this study to determine the association between complement C1q and vulnerable plaque morphology in CAD patients.
Login Or Register To Read Full Story